Chronic Active Hepatitis in Patients with and Without Hepatitis B Surface Antigenemia

Overview

Journal Infection

Date 1977 Jan 1

PMID 914364

Authors

A Par

K BARNA

G BAJTAI

M Balazs

A PATAKFALVI

A Gogl

Affiliations

Soon will be listed here.

Abstract

This study was designed to compare the clinical and immunological characteristics of the hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative (cryptogenic) forms of chronic active hepatitis. The data of 48 patients with chronic active hepatitis, 24 with persistent HBs antigenemia and 24 without HBsAg, were analysed. HBsAg was detected by counter-immunoelectrophoresis and radioimmunoassay. The clinical features, biochemical liver function tests, immunoglobulins, complement C3, antoantibodies, and cell-mediated immunoreactivity of the two forms of the disease were compared. Cirrhosis was found to occur more frequently at the time of diagnosis in the HBsAg-negative group, and the serum alkaline phosphatase level was raised significantly compared to the HBsAg-positive form. The elevation of the IgG level was greater in the cryptogenic form, but the difference was not statistically significant compared to the HBsAg-positive patients. There was a marked difference in the frequency of the mitochondrial antibodies, but not of the antinuclear factor and other autoantibody-like serum factors. Lymphoblastic transformation revealed a similar diminution in response to phytohaemagglutinin stimulation in both groups of patients compared to the normal controls. An increase of the 3H-thymidine incorporation was seen after stimulation with human liver mitochondrial antigen, and leukocyte migration inhibition could be observed with this antigen in both forms of chronic active hepatitis.

References

Bain B . Tritiated-thymidine uptake in mixed leucocyte cultures: effect of specific activity and exposure time. Clin Exp Immunol. 1970; 6(2):255-62. PMC: 1712783. View

Schumacher K . [Significance of immunologic reactions for the diagnosis and pathogenesis of chronic hepatitis]. Klin Wochenschr. 1969; 47(18):949-59. DOI: 10.1007/BF01498231. View

Doniach D, Roitt I, Walker J, Sherlock S . Tissue antibodies in primary biliary cirrhosis, active chronic (lupoid) hepatitis, cryptogenic cirrhosis and other liver diseases and their clinical implications. Clin Exp Immunol. 1966; 1(3):237-62. PMC: 1579190. View

DUDLEY F, Fox R, Sherlock S . Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet. 1972; 1(7753):723-6. DOI: 10.1016/s0140-6736(72)90234-6. View

DUDLEY F, Scheuer P, Sherlock S . Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet. 1972; 2(7792):1388-93. DOI: 10.1016/s0140-6736(72)92963-7. View

Ling C, Overby L . Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125 I-antibody. J Immunol. 1972; 109(4):834-41. View

Lindberg J, Lindholm A, Lundin P, Iwarson S . Trigger factors and HL-A antigens in chronic active hepatitis. Br Med J. 1975; 4(5988):77-9. PMC: 1674938. DOI: 10.1136/bmj.4.5988.77. View

Galbraith R, Smith M, Mackenzie R, TEE D, Doniach D, Williams R . High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med. 1974; 290(2):63-9. DOI: 10.1056/NEJM197401102900201. View

Popper H, Mackay I . Relation between Australia antigen and autoimmune hepatitis. Lancet. 1972; 1(7761):1161-4. DOI: 10.1016/s0140-6736(72)91379-7. View

10.

Mackay I, Whittingham S . "Auto-immune" chronic hepatitis. Postgrad Med. 1967; 41(1):72-83. DOI: 10.1080/00325481.1967.11696105. View

11.

Mackay I, Morris P . Association of autoimmune active chronic hepatitis with HL-A1,8. Lancet. 1972; 2(7781):793-5. DOI: 10.1016/s0140-6736(72)92149-6. View

12.

Lee W, REED W, Mitchell C, Galbraith R, Eddleston A, Zuckerman A . Cellular and humoral immunity to hepatitis-B surface antigen in active chronic hepatitis. Br Med J. 1975; 1(5960):705-8. PMC: 1672762. DOI: 10.1136/bmj.1.5960.705. View

13.

MELLA B, Lang D . Leukocyte mitosis: suppression in vitro associated with acute infectious hepatitis. Science. 1967; 155(3758):80-1. DOI: 10.1126/science.155.3758.80. View

14.

Paronetto F, Schaffner F, Popper H . Antibodies to cytoplasmic antigens in primary biliary cirrhosis and chronic active hepatitis. J Lab Clin Med. 1967; 69(6):979-88. View

15.

SCHEIFFARTH F, WARNATZ H, OTTENJANN R, Ritter H . [Lymphocyte transformation in chronic hepatitis and other hepatic diseases]. Arch Klin Med. 1969; 216(5):447-56. View

16.

Cooksley W, Powell L, MISTILIS S, Mackay I, Barker L . Hepatitis B antigen and antibody in active chronic hepatitis and other liver diseases in Australia. A multicenter collaborative study. Am J Dig Dis. 1975; 20(2):110-4. DOI: 10.1007/BF01072335. View

17.

JOSKE R, LAURENCE B, MATZ L . Familial active chronic hepatitis with hepatocellular carcinoma. Report of a case. Gastroenterology. 1972; 62(3):441-4. View

18.

Vischer T . Australia antigen and autoantibodies in chronic hepatitis. Br Med J. 1970; 2(5711):695-8. PMC: 1700632. DOI: 10.1136/bmj.2.5711.695. View

19.

Goldstein G, Lam K, MISTILIS S . Drug-induced active chronic hepatitis. Am J Dig Dis. 1973; 18(3):177-84. DOI: 10.1007/BF01071970. View

20.

Mathews J, Mackay I . Australia antigen in chronic hepatitis in Australia. Br Med J. 1970; 1(5691):259-61. PMC: 1699349. DOI: 10.1136/bmj.1.5691.259. View